Новое в консервативной терапии больных гиперплазией предстательной железы
Новое в консервативной терапии больных гиперплазией предстательной железы
Аляев Ю.Г., Винаров А.З., Локшин К.Л., Спивак Л.Г. Новое в консервативной терапии больных гиперплазией предстательной железы. Consilium Medicum. 2008; 10 (2): 45–48.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Huggins C, Steven R. The effect of castration on benign hypertrophy of the prostate in man. J Urol 1940; 43: 705.
2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293.
3. Wilson JD, Walker JD. The conversion of testosterone to b-androstan-17b-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest 1969; 48: 371–9.
4. Peterson RE, Imperato-McGinley J, Gauier T et al. Male pseudohermaphroditism due to steroid. Am J Med 1997; 62: 170–91.
5. Imperato-McGinley J, Peterson RE, Gauier T et al. Androgens and the evolution of male – gender identity among male pseudohermaphrodites with 5a-reductase deficiency. New Engl J Med 1979; 300: 1233–7.
6. Imperato-McGinley J, Gauier T, Zirinsky TH et al. Prostate visualization studies in male homozygous and heterozygous for 5a-reductase deficiency. J Clin Endocrinol Metab 1992; 75: 1022–6.
7. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185–91.
8. Gisleskog PO, Herman D, Hammarlund-Udenaes M et al. A model of the turnover of dihydrotestosterone in the presence of the irreversible 5a-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998; 64: 636–47.
9. Bramson HN, Hermann D, Batchelor KW et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496–502.
10. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5a-reductase types I and II (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–41.
11. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179–84.
12. McConnel JD, Wilson JD, Georges FW et al. Finasteride, an inhibitor of 5a-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–8.
13. Debruyne F, Barkin J, van Erps P et al. ARIA3001, ARIA3002, ARIB3001 study investigators. Efficacy and safety of along term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004, 46: 488–94.
14. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349 (25): 2387–98.
15. Roehrborn CG, Siami P, Barkin J et al. The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. J Urol 2008; 179: 616–21.
2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293.
3. Wilson JD, Walker JD. The conversion of testosterone to b-androstan-17b-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest 1969; 48: 371–9.
4. Peterson RE, Imperato-McGinley J, Gauier T et al. Male pseudohermaphroditism due to steroid. Am J Med 1997; 62: 170–91.
5. Imperato-McGinley J, Peterson RE, Gauier T et al. Androgens and the evolution of male – gender identity among male pseudohermaphrodites with 5a-reductase deficiency. New Engl J Med 1979; 300: 1233–7.
6. Imperato-McGinley J, Gauier T, Zirinsky TH et al. Prostate visualization studies in male homozygous and heterozygous for 5a-reductase deficiency. J Clin Endocrinol Metab 1992; 75: 1022–6.
7. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185–91.
8. Gisleskog PO, Herman D, Hammarlund-Udenaes M et al. A model of the turnover of dihydrotestosterone in the presence of the irreversible 5a-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998; 64: 636–47.
9. Bramson HN, Hermann D, Batchelor KW et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496–502.
10. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5a-reductase types I and II (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–41.
11. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179–84.
12. McConnel JD, Wilson JD, Georges FW et al. Finasteride, an inhibitor of 5a-reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–8.
13. Debruyne F, Barkin J, van Erps P et al. ARIA3001, ARIA3002, ARIB3001 study investigators. Efficacy and safety of along term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004, 46: 488–94.
14. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349 (25): 2387–98.
15. Roehrborn CG, Siami P, Barkin J et al. The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. J Urol 2008; 179: 616–21.
Авторы
Ю.Г.Аляев, А.З.Винаров, К.Л.Локшин, Л.Г.Спивак
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.